

Vericel to Present at BioCentury's 25th Annual Future Leaders in the Biotech Industry Conference

March 9, 2018

CAMBRIDGE, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, chief financial officer and VP of corporate development, will present the latest company overview at BioCentury's 25th Annual Future Leaders in the Biotech Industry Conference in New York, NY on Friday, March 23, 2018 at 9:00am Eastern Time.

The presentation will be live webcast at: http://www.wsw.com/webcast/biocentury5/vcel, and may be accessed from the news and events section of the Vericel website.

About Vericel Corporation

Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. Vericel is marketing MACI[®] (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel[®] (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.

Epicel® and MACl® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.

(vcel-fin)

Global Media Contacts:

David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
David.schull@russopartnersllc.com

Karen Chase Russo Partners LLC +1 646-942-5627 (office) +1 917-547-0434 (mobile) Karen.chase@russopartnersllc.com

Investor Contacts:

Chad Rubin
The Trout Group
crubin@troutgroup.com
+1 (646) 378-2947

Lee Stern
The Trout Group
lstern@troutgroup.com
+1 (646) 378-2922



Source: Vericel Corporation